Top Page
Pharmaron Beijing Co., Ltd. Class H
(Frankfurt:3759)
Pharmaron Beijing Co., Ltd. Class H (3759) vs. iShares MSCI Hong Kong ETF (EWH)
Pharmaron Beijing Co., Ltd. Class H Business Overview & Revenue Model
Pharmaron Beijing Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.70B | 12.28B | 11.54B | 10.27B | 7.44B | 5.13B |
| Gross Profit | 4.37B | 4.20B | 4.12B | 3.77B | 2.68B | 1.92B |
| EBITDA | 2.40B | 3.38B | 2.95B | 2.53B | 2.49B | 1.72B |
| Net Income | 1.87B | 1.79B | 1.60B | 1.37B | 1.66B | 1.17B |
Balance Sheet | ||||||
| Total Assets | 24.33B | 23.93B | 26.48B | 20.49B | 18.39B | 11.91B |
| Cash, Cash Equivalents and Short-Term Investments | 2.68B | 2.81B | 6.72B | 2.24B | 5.10B | 3.85B |
| Total Debt | 5.53B | 5.54B | 9.36B | 6.12B | 5.29B | 1.05B |
| Total Liabilities | 9.69B | 9.70B | 13.24B | 9.65B | 8.09B | 2.98B |
| Stockholders Equity | 14.04B | 13.62B | 12.56B | 10.55B | 10.13B | 8.87B |
Cash Flow | ||||||
| Free Cash Flow | 561.71M | 536.02M | ― | ― | ― | 332.77M |
| Operating Cash Flow | 1.16B | 2.58B | 2.75B | 2.14B | 2.06B | 1.65B |
| Investing Cash Flow | 456.45M | ― | -2.25B | ― | ― | ― |
| Financing Cash Flow | ― | ― | 3.92B | ― | 3.66B | ― |
Pharmaron Beijing Co., Ltd. Class H Technical Analysis
Pharmaron Beijing Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $1.04T | 7.22 | 6.99% | 11.71% | 37.04% | ||
76 Outperform | $88.89B | 19.33 | 13.20% | 2.56% | -9.60% | -27.18% | |
74 Outperform | $102.33B | 28.37 | 8.17% | ― | 7.52% | -1.92% | |
74 Outperform | HK$32.85B | 11.85 | 14.56% | 4.08% | -5.37% | 6.28% | |
69 Neutral | $94.79B | 49.95 | 6.14% | 11.85% | 7.63% | -24.23% | |
67 Neutral | €42.67B | 14.07 | 14.15% | 1.51% | 9.24% | 23.72% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% |
Pharmaron Beijing Co., Ltd. Class H Corporate Events
Pharmaron Beijing Co., Ltd. announced the resignation of Mr. Hu Baifeng from his role as a non-executive director and member of the strategy committee. This change is due to the reallocation of Mr. Hu’s primary work responsibilities, which may impact the company’s strategic direction and governance structure.
Pharmaron Beijing Co., Ltd. has released its first quarterly report for 2025, prepared in accordance with PRC Accounting Standards for Business Enterprises. The report, which remains unaudited, provides insights into the company’s financial performance for the quarter, potentially impacting its operations and market positioning.
Pharmaron Beijing Co., Ltd. announced the resignation of Mr. Hu Baifeng from his position as a non-executive director and member of the strategy committee. Mr. Hu will continue his duties until a new director is elected at the 2024 AGM. The company has nominated Ms. Wan Xuan as a candidate for the non-executive director position, with her appointment subject to shareholder approval at the AGM. Ms. Wan, who has a background in investment management within the healthcare and biotechnology sectors, will also serve on the strategy committee if elected.
Pharmaron Beijing Co., Ltd. has announced that its board of directors will meet on April 25, 2025, to consider and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
Pharmaron Beijing Co., Ltd. reported its annual financial results for the year ending December 31, 2024, showing a 6.4% increase in revenue to RMB12,275.8 million and a 12% rise in profit attributable to owners of the parent to RMB1,793.4 million compared to the previous year. Despite a decrease in net cash flows from operating activities by 6.4%, the company proposed a final dividend of RMB2.0 per 10 shares, reflecting its continued commitment to shareholder returns.
Pharmaron Beijing Co., Ltd. has announced a final cash dividend of RMB 2 per 10 shares for the financial year ending December 31, 2024. The distribution is contingent upon approval at the upcoming AGM, with an expected payout by the end of August 2025, reflecting the company’s solid financial performance and commitment to shareholder returns.
Pharmaron Beijing Co., Ltd. has announced several strategic initiatives, including the adoption of a new 2025 H Share Award Scheme to enhance employee loyalty and the expansion of its existing H Share Award Scheme to attract and retain talent. Additionally, the company plans to increase its registered capital and amend its articles of association to reflect these changes, aligning with recent regulatory updates and enhancing its operational framework.
Pharmaron Beijing Co., Ltd. has established a Nomination Committee to enhance its corporate governance structure. This committee is tasked with overseeing the selection and appointment of directors and senior management, ensuring a diverse and independent board composition, which is crucial for the company’s strategic direction and operational efficiency.
Pharmaron Beijing Co., Ltd. has announced a board meeting scheduled for March 26, 2025, to discuss and approve the annual results for the year ended December 31, 2024, and to consider the recommendation of a final dividend payment. This meeting is significant as it will provide insights into the company’s financial performance and potential returns for shareholders, impacting its market positioning and stakeholder interests.